Resource Summary Report

Generated by dkNET on Sep 14, 2026

OCI-AML-5

RRID:CVCL_1620
Type: Cell Line

Proper Citation

RRID:CVCL_1620

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1620

Proper Citation: RRID:CVCL_1620

Description: Cell line OCI-AML-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: PMID:9096695, PMID:16408098, PMID:21989985, PMID:22460905, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26434589, PMID:26589293, PMID:27397505, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31395879, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-AML-5

Synonyms: OCI/AML-5, OCI-AML5, OCI/AML5, OCI AML5, OCIAML5, Ontario Cancer Institute-Acute Myeloid Leukemia-5

Cross References: BTO:BTO_0004621, CLO:CLO_0008236, EFO:EFO_0006707, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:215, BioSample:SAMN03472968, BioSample:SAMN03473389, BioSample:SAMN10988502, cancercelllines:CVCL_1620, Cell_Model_Passport:SIDM00461, ChEMBL-Cells:CHEMBL4523545, ChEMBL-

Targets:CHEMBL4523576, Cosmic:787469, Cosmic:975291, Cosmic:1012111, Cosmic:1281346, Cosmic:1319548, Cosmic:2131553, Cosmic:2306234, Cosmic:2750856, Cosmic-CLP:1330983, DepMap:ACH-000065, DSMZ:ACC-247, DSMZCellDive:ACC-247, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1330983, GEO:GSM887470, GEO:GSM888550, GEO:GSM1374781, GEO:GSM1374782, GEO:GSM1446751, GEO:GSM1525023, GEO:GSM1670297, IARC_TP53:30133, LiGeA:CCLE_796, LINCS_LDP:LCL-1067, PharmacoDB:OCIAML5_1185_2019, PRIDE:PXD030304, Progenetix:CVCL_1620, PubChem_Cell_line:CVCL_1620, Wikidata:Q54931744

ID: CVCL_1620

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260913T005647+0000

Ratings and Alerts

No rating or validation information has been found for OCI-AML-5.

No alerts have been found for OCI-AML-5.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. Cell, 189(1), 215.

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. Cancer research communications, 5(4), 648.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. EBioMedicine, 118, 105822.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell stem cell, 32(3), 463.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. Cancer research communications, 5(11), 2012.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer discovery.

Shahzad U, et al. (2024) CASCADES, a novel SOX2 super-enhancer-associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. Molecular oncology.

Mill CP, et al. (2024) Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood cancer journal, 14(1), 25.

Bianchi M, et al. (2024) The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer immunology research, 12(7), 921.

Park SM, et al. (2023) Dual IKZF2 and CK1? degrader targets acute myeloid leukemia cells. Cancer cell, 41(4), 726.

Mill CP, et al. (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 139(6), 907.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. Cancer cell, 40(3), 301.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(13), 3371.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood cancer journal, 9(2), 4.